Study Details
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Clinicaltrials.gov ID
Astellas Study ID
9785-CL-0336
EudraCT ID
N/A
Condition
Prostate Cancer
Phase
Phase 3
Age
18 Years - N/A
Sex
Male
Product
enzalutamide
Type
Interventional
Trial Dates
Sep 2019 - Oct 2025
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment number
180
China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site CN86003
Shanghai, China
Site CN86026
Wuhan, China
Site CN86013
Shanghai, China
Site CN86004
Nanchang, China
Site CN86025
Fuzhou, China
Site CN86020
Shenyang, China
Site CN86035
Beijing, China
Site CN86011
Shenzhen, China
Site CN86030
Qingdao, China
Site CN86001
Guangzhou, China
Site CN86016
Changsha, China
Site CN86014
Shanghai, China
Site CN86029
Zhengzhou, China
Site CN86032
Suzhou, China
Site CN86005
Wulumuqi, China
Site CN86017
Zhengzhou, China
Site CN86028
Hangzhou, China
Site CN86012
Tianjin, China
Site CN86036
Hangzhou, China
Site CN86023
Changsha, China
Site CN86019
Wuhan, China
Site CN86022
Beijing, China
Site CN86010
Shanghai, China
Site CN86027
Shanghai, China
Site CN86021
Wuxi, China
Site CN86009
Changsha, China
Site CN86002
Shanghai, China
Site CN86038
Xi'an, China
Site CN86031
Shenzhen, China
Site CN86024
Changchun, China